Dr. Matt Thompson is an award-winning global healthcare executive and cardiovascular surgeon with a 20+ year track record of building, scaling and transforming medical device companies and clinical organisations.
Known for bridging deep clinical insight with boardroom leadership, Dr. Thompson specialises in leading public and private medical device companies through turnaround, restructuring, M&A, global market expansion and regulatory approvals.
Most recently, as the CEO of Endologix, LLC, he successfully led the post-Chapter 11 restructuring, stabilised cash flow, reduced OpEx and returned the company to double-digit revenue growth. During his tenure, he also executed the acquisition and integration of PQ Bypass.
A former Professor and Director of Cardiovascular Services at St George’s, London, he built one of Europe’s leading aortic centres, secured over £20m in research funding and published over 500 peer-reviewed papers.
Matt serves as a Non-Executive Director for NASDAQ-listed Vivos Therapeutics and is on the Board of Life Seal Vascular. He received his medical degrees from Cambridge, Leicester and London, and is a Fellow of the Royal College of Surgeons.
